Sean Khozin, MD, MPH

Independent Director, Co-Chairman – Mission Advisory Board

Sean Khozin, MD, MPH, is a Senior Life Sciences and Healthcare Partner at Braven. He is a physician-executive, board certified oncologist, and data scientist who is globally recognized as a leader in drug development, regulation, and applications of artificial intelligence and machine learning in biomedical research and therapeutic development.

Prior to joining Braven, an early-stage investor that co-builds breakthroughs in large, regulated sectors – finance, healthcare, and industrials, Sean was the Chief Executive Officer of CancerLinQ, a precision oncology enterprise focused on transforming cancer care and research with real-world data and advanced analytics. He was formerly the Global Head of Data Strategy and Data Science Innovation at Johnson & Johnson, leading a worldwide multidisciplinary team charged with the design and implementation of pioneering data science solutions to support the development of innovative new medicines and vaccines.

He also was a founding member of the US FDA’s Oncology Center of Excellence and Executive Director of Information Exchange and Data Transformation (INFORMED), the FDA’s first data science and technology incubator that he established under special federal authorities. As a uniquely entrepreneurial sandbox housed within the agency responsible for regulating nearly a third of the US economy, INFORMED played a pivotal role in shaping the US FDA’s position on real-world evidence and catalyzing the use of novel data science solutions in drug discovery and clinical development.

Before his tenure in the US federal government, Sean was the cofounder of Hello Health, a technology company focused on developing integrated telemedicine, point-of-care data visualization, and advanced analytical systems for optimizing patient care and clinical research. The company’s core technology offerings were first operationalized in a multidisciplinary network of clinics he had founded called SKMD.

Sean is a Research Affiliate at the MIT Laboratory for Financial Engineering, where he combines his quantitative and life sciences expertise in support of novel financing strategies for improving the lives of patients with cancer. He has over a decade of clinical and basic science research experience at the US National Cancer Institute and currently serves on the boards of Alliance for Artificial Intelligence in Healthcare and the Digital Medicine Society.